Pharma & Biotech GWiR 13 March 2009 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Brazil/Europe/India: Concerns continue over generics drug seizures as legality debates begin (Intellectual Property Watch) (Intellectual Property Watch) (Intellectual Property Watch)

Indian generic manufacturers concerned anti-counterfeit legislation may threaten market in Uganda and surrounding territories (Afro-IP)

US: Rep Waxman introduces Follow-On Biologics Bill; legislation hews closely to Hatch-Waxman exclusivity paradigm (FDA Law Blog) (Law360) (Patent Docs) (Patent Baristas)

 
General

WHO launches online hearing on innovative funding sources for R&D (Intellectual Property Watch)

Greece: SPC Blog’s tour of European Patent Offices – Greece (The SPC Blog)

Brazil/Europe/India: Concerns continue over generics drug seizures as legality debates begin (Intellectual Property Watch) (Intellectual Property Watch) (Intellectual Property Watch)

EU: Biosimilars in the EU: delivering the goods? (GenericsWeb)

India’s Human Genome Bill (Spicy IP)

Indian drugmakers push into US generics market (GenericsWeb)

Uganda: Indian generic manufacturers concerned anti-counterfeit legislation may threaten market in Uganda and surrounding territories (Afro-IP)

UK: Court of Appeal admonishes counsel for dilatory actions involved in parallel British and EPO proceedings: Eli Lilly & Co v Human Genome Sciences (Hal Wegner) (PatLit)

US: President Obama to lift stem cell limits on Monday (Patent Docs) (Law360)

US: Rep Waxman introduces Follow-On Biologics Bill; legislation hews closely to Hatch-Waxman exclusivity paradigm (FDA Law Blog) (Law360) (Patent Docs) (Patent Baristas)

US: What is the impact of gene patents and licensing practices? (Patent Baristas)

US: Schering merger includes legal headaches for Merck, including IP suits (Law360)

US: Lessig and Eisen article ‘Is John Conyers Shilling for Special Interests’ concerning proposal to ban open access publishing requirement for taxpayer funded medical scientists (Huffington Post) (Lessig) (Lenz Blog) (Lessig) (Lenz Blog) (Michigan Messenger) (Lessig)

US: McCain touts drug imports to lower US costs (Law360)

US: Biotech and pharma provide little support in Bilksi’s petition for certiorari (Holman’s Biotech IP Blog)

US: Final judgment granted to Applera in patent dispute with Enzo (Patent Docs) (Law360)

US: Life Technologies seeks to invalidate Oxford Biomedical Research patent relating to method of purifying proteins in engineered DNA (Law360)

 
Products

Abelcet (Amphotericin B) – France: Patent Office refuses Liposome Co’s SPC application relating to Abelcet (The SPC Blog)

Actonel (Risedronic acid) – US: Procter & Gamble files patent infringement suit against Apotex over generic Actonel ANDA (Patent Docs)

Cenestin (Estrogens) – US: Duramed Pharmaceuticals files patent infringement suit against Paddock Lab’s to block generic Cenestin (Patent Docs)

Cipralex (Escitalopram) – Israel Patent Office refuses to grant patent term extension for Cipralex: Unipharm v Lundbeck (The IP Factor)

Evista (Raloxifene) – US: Teva hit with temporary restraining order in Evista feud with Eli Lilly (Law360) (GenericsWeb)

Evoclin (Clindamycin) – US: FDA receives 4th citizen petition on QI Act and 30-month stay issues; latest petition concerns Evoclin (FDA Law Blog)

Gemzar (Gemcitabine) – EU: Actavis launches Gemcitabine on patent expiry in EU markets (GenericsWeb)

MetroGel (Metronidazole) – US: Galderma Lab’s files patent infringement suit in response to Tolmar’s generic MetroGel ANDA (Patent Docs)

Naprelan (Naproxen) – US: Watson Pharma and Elan settle patent suit over Naprelan (SmartBrief) (Patent Docs) (Law360) (GenericsWeb)

Prilosec (Omeprazole) – US: Federal judge dismisses AstraZeneca’s patent lawsuit against Dr Reddy’s over generic Prilosec (Law360)

Prilosec (Omeprazole) – US: Supreme Court denies Apote&xrsquo; writ of certiorari in Prilosec case against AstraZeneca (Patent Docs) (Law360)

ReFacto – US: Novartis asserts rights over two patents in ongoing battle with Genetics Institute over who legally owns formula for ReFacto (Law360)

Renagel (Sevelamer) – US: Genzyme files patent infringement lawsuit following Lupin’s ANDA to manufacture generic Renagel (Patent Docs) (Law360) (GenericsWeb)

Xopenex (Levalbuterol) – US: Sepracor reaches settlement with Barr Lab’s over Xopenex (Law360) (GenericsWeb)

 

%d bloggers like this: